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Abstract
The role of amino acids as substrates for protein synthesis is well documented. However, a
function for amino acids in modulating the signal transduction pathways that regulate mRNA
translation has only recently been described. Interesting, some of the signaling pathways regulated
by amino acids overlap with those classically associated with the cellular response to hormones
such as insulin and insulin-like growth factors. The focus of this review is on the signaling pathways
regulated by amino acids, with a particular emphasis on the branched-chain amino acid leucine, and
the steps in mRNA translation controlled by the signaling pathways.
Introduction
Recent advances in biomedical research reveal a key role
for amino acids as nutritional signals in the regulation of
a number of cellular processes. Studies employing a vari-
ety of cell types and different tissues demonstrate that one
such process affected is the regulation of gene expression
through modulation of the translation of messenger RNA
(mRNA). The studies show that cells recognize changes in
amino acid availability and generate alterations in signal
transduction pathways that are also regulated by hor-
mones and growth factors. The cells then respond to the
integrated signaling input by either upregulating or down-
regulating translation initiation, i.e., the process during
which initiator methionyl-tRNA (met-tRNAi) and mRNA
bind to a 40S ribosomal subunit followed by the joining
of a 60S ribosomal subunit to form a translationally com-
petent 80S ribosome. The response of translation initia-
tion to a change in amino acid and/or hormone
availability can be general, i.e., affecting the translation of
most if not all mRNAs, and/or specific, i.e., affecting the
translation of a single class or subset of mRNAs. Both the
general and specific responses can be mediated through
regulation of either the met-tRNAi and/or mRNA binding
steps. The specific response may also involve an addi-
tional regulatory site, i.e., the phosphorylation status of
ribosomal protein rpS6, one of the proteins composing
the 40S ribosomal subunit. Learning how the cell recog-
nizes a sufficiency of amino acids is presently the objective
of intense research. Present evidence, however, suggests
multiple recognition sites and multiple signaling path-
ways. Below, we summarize our current knowledge of the
signaling pathways known to respond to changes in
amino acid availability. In addition, the translation initi-
ation factors and mRNA structural elements that are
involved in changes in both global and specific modula-
tion of mRNA translation are discussed.
mRNA translation initiation
The first step in translation initiation involves the binding
of met-tRNAi to the 40S ribosomal subunit, a reaction
mediated by the eIF2•GTP complex [reviewed in [1]]. In a
subsequent step, the GTP bound to eIF2 is hydrolyzed to
GDP and eIF2 is released from the 40S subunit complexed
with GDP, leaving met-tRNAi behind. Exchange of GDP
bound to eIF2 for GTP is mediated by the guanine nucle-
otide exchange factor eIF2B, and as described below, there
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are at least three known mechanisms for modulating
eIF2B activity in vivo.
The second step in translation initiation involves the
binding of mRNA to the 40S ribosomal subunit contain-
ing the eIF2•GTP•met-tRNAi complex and eIF3 [1]. The
protein that mediates this step is a heterotrimeric complex
referred to as eIF4F which consists of the initiation factors
eIF4A, eIF4E, and eIF4G. eIF4A is an RNA helicase that
serves to unwind secondary structure in the 5'-untrans-
lated region (5'-UTR) of the mRNA, allowing the 40S
ribosomal subunit to migrate from the 5'-m7GTP cap to
the AUG start codon. The helicase activity of eIF4A is stim-
ulated by eIF4B and eIF4H. eIF4E binds to the m7GTP cap
at the 5'-end of the mRNA and thus plays a crucial role in
the binding of the mRNA to the ribosome. eIF4G is a scaf-
folding protein that binds to eIF4A, eIF4E, and eIF3. Thus,
eIF4G is a molecular bridge that links the mRNA, which is
bound by eIF4E, to the 40S ribosomal subunit, which is
bound by eIF3. Assembly of the eIF4F complex is regu-
lated in part through the reversible association of eIF4E
with the translational repressors, eIF4E-binding proteins
4E-BP1, 4E-BP2, and 4E-BP3. The domain on eIF4E to
which eIF4G binds overlaps with the binding domain for
the 4E-BPs, such that either eIF4G or 4E-BP can bind to
eIF4E, but both cannot bind at the same time. Thus, asso-
ciation of eIF4E with a 4E-BP precludes the binding of
mRNA to the 40S ribosomal subunit by preventing the
binding of the eIF4E•mRNA complex with eIF4G. Associ-
ation of eIF4E with the 4E-BPs is regulated by phosphor-
ylation of 4E-BP, whereby hypophosphorylated 4E-BPs
bind to eIF4E but the hyperphosphorylated proteins do
not.
Regulation of mRNA translation through 
Phosphorylation of eIF2 or eIF2B
Of the three known mechanisms for regulating eIF2B
activity, the best characterized involves phosphorylation
of eIF2 on Ser51 of its α-subunit. Phosphorylation of
eIF2α converts eIF2 from a substrate into a competitive
inhibitor of eIF2B and represses the translation of most
mRNAs, but paradoxically enhances the translation of
mRNAs containing multiple upstream open reading
frames (uORF) and internal ribosome entry sites (IRESs).
Phosphorylation of eIF2α is mediated by any of four
known eIF2α kinases in mammalian cells: the mamma-
lian ortholog of the yeast general control non-derepress-
ing kinase-2 (mGCN2), the heme-regulated inhibitor
(HRI), the protein kinase dsRNA-activated (PKR), and the
PKR-like endoplasmic reticulum kinase [PERK, reviewed
in [2]] (Fig. 1). In both cells in culture [e.g. [3]] and livers
perfused in situ [4], deprivation of single essential amino
acids promotes phosphorylation of eIF2α with a concom-
itant inhibition of eIF2B. The phosphorylation of eIF2α
that occurs in vivo [5], in perfused rat liver [6], and in cells
in culture [7] in response to altered amino acid availabil-
ity is mediated by the eIF2α protein kinase referred to as
mGCN2. In yeast deprived of amino acids, uncharged
tRNA accumulates and binds to a domain on Gcn2p that
exhibits sequence homology to histidyl-tRNA synthetase
resulting in its activation [reviewed in [5]]. In fasted rats,
feeding a meal containing a complete mixture of essential
amino acids stimulates protein synthesis in the liver and
skeletal muscle, but has no effect on eIF2α phosphoryla-
tion or eIF2B activity [8]. In contrast, feeding a diet lacking
a single essential amino acid results in both an increase in
eIF2α phosphorylation and a reduction in eIF2B activity
in liver [9], suggesting that an imbalance in plasma con-
centrations of essential amino acids results in activation of
signaling pathways within the liver that result in increased
phosphorylation of eIF2α. The enhanced phosphoryla-
tion of eIF2α that occurs in response to an imbalanced
amino acid mixture is mediated by the eIF2α kinase
mGCN2, because in mice lacking the kinase, feeding a
diet lacking leucine does not promote eIF2α phosphoryla-
tion or inhibition of eIF2B [5]. However, the mechanism
through which severe amino acid deprivation activates
mGCN2 in cells in culture, i.e. accumulation of uncharged
tRNA, probably isn't relevant in vivo because plasma
amino acids are typically maintained at concentrations
well above the Km of the aminoacyl-tRNA synthetases,
even during fasting, and therefore significant amounts of
uncharged tRNA are unlikely to accumulate. Modulation
of eIF2α phosphorylation also occurs in response to
changes in the availability of nutrients other than amino
acids. For example, either hypoglycemia or hyperglycemia
promotes eIF2α phosphorylation. Hypoglycemia is
thought to activate the endoplasmic reticulum-associated
eIF2α kinase termed PERK through induction of the ER
stress response [10]. However, the kinase that phosphor-
ylates eIF2α in response to hyperglycemia is unknown. In
vivo, the transient hypoglycemia that occurs shortly after
birth results in altered translation of mRNAs encoding
several transcription factors such as C/EBPβ that induce
the transcription of a number of genes involved in gluco-
neogenesis and glucose storage such as PEPCK, glucose-6-
phosphatase, pyruvate carboxylase, and glycogen syn-
thetase [11]. A recent study using mice containing a
homozygous mutation in the gene encoding eIF2α that
replaces Ser51 with an unphosphorylatable Ala residue
(eIF2S51A) demonstrated that phosphorylation of eIF2α
is a critical component in the response of the newborn to
hypoglycemia [12]. Thus, in neonatal eIF2S51A mice, the
activity of PEPCK in the liver is significantly reduced com-
pared to wildtype mice and its induction immediately
after birth is severely attenuated. The mechanism through
which eIF2α phosphorylation might promote induction
of PEPCK gene transcription is as yet unexplored, but has
been postulated to be a consequence of altered translationNutrition & Metabolism 2004, 1:3 http://www.nutritionandmetabolism.com/content/1/1/3
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of mRNAs encoding specific transcription factors, e.g. C/
EBPα and C/EBPβ.
HRI was first identified in rabbit reticulocytes and shown
to be activated in response to hyperoxia and iron and
heme deficiency [13]. Subsequent studies have shown
that HRI is also expressed in multiple tissues and is acti-
vated by heavy metals and nitric oxide (NO). In fact, NO
binds directly to HRI [14]. Because non-erythroid cells sel-
dom experience large fluctuations in heme content, it has
been suggested that NO may be a principle regulator of
HRI in such cells [14].
PKR is a ubiquitously expressed serine-threonine protein
kinase that is activated by double-stranded RNA and is
induced by interferon [reviewed in [15]]. PKR is also acti-
vated by lipopolysaccharide and cytokines such as IL-1
and TNF-α, and is a key component of the proinflamma-
tory response to bacterial infection. It is a potent inhibitor
of cell growth when over-expressed in yeast, mammalian,
Regulation of eIF2α phosphorylation Figure 1
Regulation of eIF2α phosphorylation. Phosphorylation of eIF2α is mediated by four known protein kinases that are regulated 
by diverse cellular stresses. Phosphorylation of eIF2α inhibits eIF2B which can have both general and specific effects on mRNA 
translation as described in detail in the text.Nutrition & Metabolism 2004, 1:3 http://www.nutritionandmetabolism.com/content/1/1/3
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or insect cells, an effect that is mediated by eIF2α phos-
phorylation because co-expression of a non-phosphor-
ylatable eIF2α prevents the growth repressive effect [16].
Unlike the other three eIF2α kinases, eIF2α is not the only
substrate for PKR; for example, PKR is reported to
phosphorylate the regulatory subunit of protein phos-
phatase 2A [17]. PKR also binds to the IκB kinase complex
and is involved in NF-κB signaling.
In addition to changes in eIF2α phosphorylation, eIF2B
activity can be altered through changes in expression of
the catalytic ε-subunit. Knockdown of the catalytic ε-sub-
unit using RNAi essentially halts cell growth and triggers
apoptosis [18]. In contrast, overexpression of eIF2Bε, as
occurs in many transformed cells, results in increased
growth [19]. Because the ε-subunit alone is not inhibited
by phosphorylated eIF2, overexpression of eIF2Bε pro-
vides a means of enhancing mRNA translation under
stress conditions that promote eIF2α phosphorylation.
The mechanism(s) through which eIF2Bε expression is
regulated are unknown, but our laboratory has found that
a preferential increase in eIF2Bε expression occurs in
response to acute resistance exercise and is blocked by pre-
treatment with rapamycin, a specific inhibitor of the
mammalian target of rapamycin (mTOR) (unpublished
observation). Because both nutrients and growth-promot-
ing hormones stimulate the mTOR signal transduction
pathway (see the next section for further discussion of
mTOR signaling), it is tempting to speculate that expres-
sion of eIF2Bε might be enhanced by such stimuli.
The guanine nucleotide exchange activity of eIF2B may
also be subject to regulation through phosphorylation of
its ε-subunit. In vitro, at least four kinases phosphorylate
eIF2Bε including casein kinases (CK)-I and -II, glycogen
synthase kinase (GSK)-3, and DYRK. Phosphorylation of
eIF2Bε b y e i t h e r  C K- I  [ 2 0 ]  or  C K - I I  [ 2 0, 2 1 ]  r e po r t e d l y
stimulates the activity of eIF2B, although this conclusion
has been questioned by another group [22]. Whether or
not phosphorylation by GSK-3 alters the activity of eIF2B
is likewise controversial. One study [20] reports that phos-
phorylation by GSK-3 has no direct effect on eIF2B activ-
ity, even though phosphorylation by GSK-3 prevents the
subsequent phosphorylation, and thus activation, by CK-
I. In contrast, other studies suggest that phosphorylation
of Ser535 in rat eIF2Bε (Ser540 in the human sequence)
by GSK-3 is required, but not sufficient, for inhibition of
eIF2B activity by insulin [23].
Regulation of mRNA translation through 
downstream targets of the mTOR signaling 
pathway
The protein kinase mTOR is a common intermediate in
both nutrient and hormone signal transduction pathways
(Fig. 2). Signaling through mTOR is enhanced by nutri-
ents and anabolic hormones, such as insulin or IGF-I
[24,25], and repressed by elevation of cAMP [25-27] or
activation of AMPK [28-30], suggesting that one function
of mTOR is to integrate the anabolic response to nutrients
and insulin and the catabolic response to counter-regula-
tory hormones, such as glucagon. However, mTOR may
not be a direct target of nutrient and hormone signaling.
Instead, a number of recent studies have identified
TSC1•TSC2 as a potential branch point in the nutrient,
insulin, and AMPK signaling pathways to mTOR [31,32].
The results of these studies support a model wherein insu-
lin and leucine would repress the inhibitory action of
TSC1•TSC2 on mTOR signaling whereas glucagon would
stimulate it. In this model, insulin stimulates signaling to
mTOR through Akt-mediated phosphorylation of TSC2.
Leucine would also modulate signaling through mTOR
through the TSC1•TSC2 complex. However, the mecha-
nism through which leucine signals to TSC1•TSC2 is
unknown, but is distinct from Akt. Leucine may also mod-
ulate signaling through mTOR by altering the association
of the kinase with one or more regulatory proteins, such
as the regulatory associated protein of mTOR (raptor) and
G protein β-subunit-like protein (GβL). In the paragraphs
that follow, the evidence supporting these various mecha-
nisms for regulating mTOR is discussed.
The activity of mTOR toward downstream targets such as
4E-BP1 and S6K1 is controlled in part through the inter-
action of mTOR with the regulatory proteins raptor and
GβL. Evidence linking raptor with nutrient signaling
through mTOR is provided by studies wherein raptor
expression was downregulated using siRNA [33,34]. In
such studies, leucine-induced phosphorylation of S6K1 is
greatly repressed to an extent similar to that observed in
cells in which mTOR expression is reduced. In part, leu-
cine may modulate signaling through mTOR by altering
the stability of the mTOR•raptor complex. In this regard,
in one study the stability of the mTOR•raptor complex
was found to be enhanced in cells subjected to amino acid
deprivation [33]. However, a study by another group [35]
failed to observe a change in binding of raptor to mTOR
in cells starved for amino acids. In part, this discrepancy
may be explained by the identification of GβL as a second
mTOR-interacting protein [34]. Like raptor, GβL has been
shown to co-immunoprecipitate with mTOR [34]. GβL is
a positive regulator of mTOR because co-expression of
GβL with mTOR results in greatly increased kinase activity
of mTOR toward 4E-BP1 and S6K1 compared to expres-
sion of mTOR alone [34]. Moreover, reducing GβL expres-
sion using siRNA represses leucine- and serum-induced
phosphorylation of S6K1 [34], suggesting that GβL is
involved in hormone and amino acid signaling though
mTOR. Importantly, GβL is necessary for leucine-medi-
ated changes in mTOR•raptor association. In cells
deprived of leucine, the binding of both raptor and GβL isNutrition & Metabolism 2004, 1:3 http://www.nutritionandmetabolism.com/content/1/1/3
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Regulation of the mTOR signaling pathway Figure 2
Regulation of the mTOR signaling pathway. The mTOR signaling pathway is controlled through various upstream kinases (e.g. 
AMPK, AKT, and MK2) that converge on the tuberous sclerosis complex, TSC1•TSC2. TSC2 is a GTPase-activator protein for 
Rheb which is a positive effector of signaling through mTOR. mTOR signals to downstream targets such as 4E-BP1 and S6K1 as 
a complex with the regulatory proteins raptor and GβL as described in detail in the text.Nutrition & Metabolism 2004, 1:3 http://www.nutritionandmetabolism.com/content/1/1/3
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high and readdition of leucine to leucine-deprived cells
decreases the amount of raptor, but not GβL, associated
with mTOR [34]. However, leucine-induced changes in
mTOR•raptor association requires GβL, suggesting that
the binding of GβL to mTOR renders the binding of raptor
to mTOR sensitive to changes in amino acid availability.
The most proximal upstream protein that has been iden-
tified in the mTOR signaling pathway is the Ras homolog
enriched in brain (Rheb). Rheb is a small G protein that
enhances phosphorylation of S6K1, rpS6, and 4E-BP1 in
an mTOR-dependent fashion when overexpressed
[reviewed in [31,36]]. Moreover, in cells overexpressing
Rheb, S6K1 phosphorylation is maintained during starva-
tion for amino acids, suggesting that Rheb is involved in
transducing signals from amino acids through mTOR
[37,38]. Rheb activity is controlled in part by a GTPase
activating protein (GAP) referred to as TSC2 or tuberin.
TSC2, and its binding partner TSC1 (a.k.a. harmartin)
were originally identified as the product of two genes that
are causative in the autosomal dominant syndrome tuber-
ous sclerosis [reviewed in [39-43]]. Mutations in either
gene are associated with the widespread development of
benign growths in multiple organs and tissues, suggesting
that the normal role of these proteins is to restrict cell size
and proliferation. This idea has been confirmed in studies
in which the Drosophila orthologs of TSC1 and TSC2,
dTsc1 and dTsc2, respectively, were shown to function in
a complex that acts downstream of AKT but upstream of
Drosophila TOR (dTOR) to restrict cell growth and prolif-
eration [44-46]. Studies in both Drosophila [47] and
mammalian cells [48] have implicated TSC1 and TSC2 in
amino acid signaling through TOR. In Drosophila, down-
regulated expression of either protein causes cells to
become resistant to amino acid deprivation [47]. Thus,
S6K phosphorylation is largely maintained during amino
acid starvation in cells with reduced expression of either
dTsc1 or dTsc2 [47]. Similarly, in mammalian cells lack-
ing either TSC1 or TSC2, S6K1 phosphorylation is resist-
ant to amino acid deprivation [49]. Moreover, in
mammalian cells in culture, co-overexpression of TSC1
and TSC2 prevents amino acid-dependent activation of
S6K1 [48]. Together, these studies strongly suggest that
TSC1 and TSC2 are required for amino acid induced sign-
aling through mTOR.
The mechanism(s) involved in the regulation of TSC2
GAP activity are poorly understood, but likely involve
phosphorylation of the protein by multiple upstream pro-
tein kinases. For example, TSC2 has been shown to be
directly phosphorylated by AKT on multiple serine and
threonine residues and phosphorylation by AKT represses
the inhibitory action of the TSC1/TSC2 complex on sign-
aling through mTOR to 4E-BP1 and S6K1 [50-53]. Like-
wise, phosphorylation of TSC2 by the MAP kinase
regulated protein, MK2, reportedly inhibits TSC2 and
leads to activation of mTOR [54]. In contrast, phosphor-
ylation by the AMP-activated protein kinase (AMPK) on
distinct residues activates TSC2 and results in repressed
signaling through mTOR, suggesting that the GAP activity
of TSC2 is enhanced by AMPK [55]. Until recently, the
kinase that regulates AMPK was unknown. However, a
recent study reports that LKB1 phosphorylates AMPK on
the activating residue, Thr172, and likely represents an
authentic AMPK kinase [56]. LKB1 was originally identi-
fied as a tumor suppressor that functions to limit cell
growth, and is ubiquitously expressed in mammalian tis-
sues [57,58]. Alone, LKB1 does not phosphorylate AMPK,
but when complexed with two adapter proteins, STRAD
and MO25, it exhibits potent AMPK activity [56]. Two iso-
forms (α and β) of each protein exist in human cells, and
the complex of LKB1 with the α-isoform of each protein,
i.e. LKB1•STRADα•MO25α, exhibits greater AMPK kinase
activity compared to other permutations of the complex
[56]. In addition to enhancing its AMPK kinase activity,
STRAD and MO25 also target LKB1 to the cytoplasm;
LKB1 normally is found primarily in the nucleus [59]. LKB
has multiple phosphorylation sites and mutation of either
Thr336 or Ser431 prevents LKB1 from inhibiting cell
growth [60]; Thr336 is an autophosphorylation site,
whereas Ser431 is phosphorylated by both PKA and p90rsk
[61]. These studies provide a possible mechanism by
which glucagon might downregulate mTOR activity, i.e.
phosphorylation of LKB1 by PKA might repress the AMPK
kinase activity of LKB1. However, such an idea is still spec-
ulative at this point as the effect of LKB1 phosphorylation
by PKA on its ability to phosphorylate AMPK has yet to be
investigated.
mRNA cis-acting elements mediating 
translational control
Changes in translation initiation can manifest as either
altered translation of most or all mRNAs (i.e. global
changes) or as altered translation of mRNAs encoding spe-
cific proteins. The mRNAs that encode proteins whose
expression are specifically regulated through changes in
mRNA translation (as opposed to changes in global
mRNA translation) typically have one or more structural
elements within the 5'-untranslated region (5'-UTR) that
mediate translational control. Examples of such elements
include multiple upstream open reading frames (uORF),
internal ribosome entry sites (IRES), highly structured 5'-
UTRs, terminal oligopyrimidine (TOP) tracts immediately
downstream of the 5'-m7GTP cap, and binding domains
for specific regulatory proteins (e.g. the iron-responsive
element in the ferritin mRNA). Each of these elements
serves to modulate the translation of a subset of mRNAs
in response to various stimuli. For example, uORF ele-
ments repress the translation of most mRNAs under nor-
mal growth conditions. The translation of mRNAs bearingNutrition & Metabolism 2004, 1:3 http://www.nutritionandmetabolism.com/content/1/1/3
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multiple uORFs is paradoxically enhanced in response to
phosphorylation of the α-subunit of eIF2, an event that is
associated with repressed translation of most mRNAs. The
mechanism through which eIF2α phosphorylation
enhances the translation of mRNAs containing multiple
uORFs is complex and involves inhibition of the guanine
nucleotide exchange activity of a second translation initi-
ation factor, eIF2B, by phosphorylated eIF2. Examples of
enhanced translation of mRNAs containing uORFs con-
comitant with eIF2α phosphorylation include the induc-
tion of the transcription factors ATF4 in mouse embryo
fibroblasts deprived of amino acids (5) and CD36 in
response to hyperglycemia (6) and the induction of the
cationic amino acid transporter (CAT-1) in response to
deprivation of amino acids [62] or glucose [63]. However,
although enhanced translation of mRNAs with uORF
sequences has been demonstrated in yeast and in cell
lines, a similar phenomenon has not been demonstrated
in an intact tissue.
A second 5'-UTR structure that allows preferential transla-
tion when eIF2α is phosphorylated is an IRES. An IRES
allows the ribosome to bind to an internal site in the 5'-
UTR and bypass the normal route of association with the
mRNA, i.e. binding to the 5'-cap structure [reviewed in
[64,65]]. The best characterized IRES-containing mRNA
that is regulated by eIF2 phosphorylation is that encoding
CAT-1 [62]. Like many IRES-containing mRNAs, the 5'-
UTR of the CAT-1 mRNA has both an IRES and uORFs,
and both elements are required for optimal regulation of
CAT-1 mRNA translation. Thus, translation of an uORF
adjacent to the IRES promotes a rearrangement of the
IRES structure, resulting in its activation. However, this
mechanism alone is unlikely to account completely for
the enhanced translation of the CAT-1 mRNA because
enhanced CAT-1 synthesis is delayed several hours after
induction of eIF2α phosphorylation, suggesting that syn-
thesis of another protein might be required for translation
of the CAT-1 mRNA. Proteins that bind to IRES elements
and modulate their function are referred to as IRES-trans-
acting factors (ITAFs). Although poorly characterized, it
has been suggested that ITAFs function as RNA chaper-
ones that, upon binding to the IRES, promote refolding of
the domain into the correct structure for 40S ribosome
binding. Examples of ITAFs include the polypyrimidine
tract binding protein (PTB) and upstream of N-ras (unr)
that activate the Apaf-1 IRES [66].
Although eIF2α phosphorylation is one mechanism for
enhancing the translation of mRNAs containing an IRES
element(s), it is not unique. For example, during apopto-
sis or infection by certain types of viruses, eIF4G is
cleaved. The normal function of eIF4G is to assemble the
translation initiation factors eIF4A and eIF4E and the
poly(A) binding protein into a complex that mediates the
binding of mRNA to the 40S ribosomal subunit. Cleavage
of eIF4G during apoptosis or viral infection separates the
binding domain for PABP and the mRNA cap binding
protein, eIF4E, from the domains that bind eIF4A and
allow ribosome attachment (referred to as the middle
fragment of eIF4G or M-FAG). A recent study reported that
M-FAG generated in etoposide-treated cells M-FAG pro-
motes the preferential translation of certain, but not all,
IRES-containing mRNAs including Apaf-1 and death-
associated protein (DAP)-5 [67]. Moreover, a number of
IRES-containing mRNAs are preferentially translated
under conditions that promote dephosphorylation or
decreased function of eIF4E, for example when eIF4E is
associated with one of the eIF4E binding proteins such as
4E-BP1. Thus, IRES function can be regulated through
multiple mechanisms.
Another structural element within the 5'-UTR of some
mRNAs that is involved in selective mRNA translation is
an oligopyrimidine tract, referred to as a TOP sequence,
immediately downstream of the 5'-cap structure [68,69].
Messages containing a TOP sequence include those
encoding the ribosomal proteins, eukaryotic elongation
factors-1A and 2, PABP, and eIF4G; in other words, pro-
teins involved in protein synthesis. Thus, enhanced trans-
lation of TOP mRNAs is one mechanism for increasing
ribosome biogenesis and the long-term capacity to syn-
thesize protein. In liver of fasted rats, inhibition of mTOR
by rapamycin prevents completely the leucine-induced
phosphorylation of S6K1 and rpS6 as well as the increased
association of TOP mRNAs with polysomes, suggesting an
important role for S6K1 activation in the regulation of
TOP mRNA translation [70]. Similarly, rapamycin pre-
vents the feeding-induced increase in S6K1
phosphorylation in liver and skeletal muscle of neonatal
pigs [71]. However, recent studies [72-74] suggest that
activation of S6K1 may not be the only mechanism for
enhancing translation of TOP mRNAs, although possible
alternatives have not been identified.
Most mRNAs that are efficiently translated, e.g. GAPDH
and β-actin, have 5'-UTRs that are short (<200 nt), have a
low content of G and C residues, and are relatively
unstructured [75]. In contrast, other mRNAs contain long,
highly-structured 5'-UTRs. It isn't surprising that in order
for the 40S ribosome to reach the AUG start codon of
mRNAs with highly-structured 5'UTRs, the RNA helicase
activity of eIF4A is essential. However, the results of a
recent study suggest that both eIF4A and the eIF4A
enhancer eIF4B are required for optimal translation of
most mammalian mRNAs, including those such as the β-
actin mRNA [76]. Although little is known about the
mechanism(s) through which eIF4A and eIF4B might be
regulated, eIF4B is phosphorylated on Ser422 in vitro by
S6K1 and leucine-deprivation of cells in culture promotesNutrition & Metabolism 2004, 1:3 http://www.nutritionandmetabolism.com/content/1/1/3
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dephosphorylation of eIF4B [77]. Thus, eIF4B phosphor-
ylation by S6K1 provides a possible link between hor-
mone and nutrient signaling through mTOR and eIF4A/
eIF4B function.
Secondary structure may also function as a cis-acting reg-
ulatory element through the binding of specific trans-act-
ing factors. A well-characterized example of such
regulation is the modulation of ferritin and δ-aminole-
vulinate (ALA) synthase mRNA translation in response to
changes in iron availability [78]. Both the ferritin and ALA
synthase mRNAs contain hairpin structures near the 5'-
end of their mRNAs, termed an iron-responsive element
(IRE), that specifically binds to the IRE-binding proteins
IRP1 and IRP2. Low intracellular iron enhances the IRE
binding activity of IRP1 and the stability of IRP2 allowing
them to bind to the IRE structure and stabilize it. Because
of its proximity to the 5'-cap structure, the IREIRP1/2
complex blocks the binding of the 40S ribosome to the
mRNA, thereby preventing translation of the ferritin and
ALA synthase mRNAs.
Conclusions
Nutrients, and in particular certain amino acids, play
important roles in the control of gene expression through
their ability to modulate the initiation phase of mRNA
translation. All essential amino acids have the potential to
globally regulate mRNA translation through the eIF2α
kinase mGCN2. In addition, changes in eIF2α phosphor-
ylation can selectively modulate the translation of mRNAs
encoding particular proteins if the 5'UTR of the mRNA
contains uORFs and/or IRES elements. Selective control of
mRNA translation can also occur through changes in sig-
naling through mTOR. Activation of S6K1 by mTOR leads
to phosphorylation of rpS6 and eIF4B which is thought to
promote preferential translation of TOP mRNAs and
mRNAs with highly structured 5'-UTRs, respectively. In
addition, mTOR phosphorylates the eIF4E binding pro-
teins leading to enhanced assembly of the eIF4F complex.
In combination with eIF4B phosphorylation, enhanced
eIF4F assembly leads to preferential translation of mRNAs
with highly structured 5'-UTRs. Although other amino
acids have been shown to increase signaling through
mTOR, leucine is arguably the most potent of the amino
acids in activating the pathway.
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